Nanoparticles embedding nucleotide-based antibodies for innovative cancer immunotherapy

This project tackles limitations of current immunotherapies targeting inhibitory immune checkpoints like PD-1 and CTLA-4, which are effective in only a minority of patients. It highlights the need for strategies that initiate the cancer immunity cycle through innate immune activation. The focus is on phagocytosis checkpoint inhibitors, which have shown limited efficacy. To overcome these issues, the authors propose local and sustained delivery of antibody-encoding plasmid DNA using nanoparticles, aiming to enhance therapeutic effects while reducing systemic toxicity.